The phase I/Ib clinical trials of prexasertib for patients with advanced or metastatic solid tumors included CRC patients with KRAS and/or BRAF mutations (NCT02860780) and CRC patients with KRAS wild type CRC who has failed to oxaliplatin- and irinotecan-based chemotherapy (NCT02124148) to evaluate safety of the combinations of prexasertib with ralimetinib or cetuximab, respectively [250]. This evidence concerns the gene BRAF and colorectal carcinoma.